Expected and paradoxical effects of obesity on cancer treatment response

被引:0
作者
Marco Gallo
Valerio Adinolfi
Viola Barucca
Natalie Prinzi
Valerio Renzelli
Luigi Barrea
Paola Di Giacinto
Rosaria Maddalena Ruggeri
Franz Sesti
Emanuela Arvat
Roberto Baldelli
Emanuela Arvat
Annamaria Colao
Andrea Isidori
Andrea Lenzi
Roberto Baldell
M. Albertelli
D. Attala
A. Bianchi
A. Di Sarno
T. Feola
G. Mazziotti
A. Nervo
C. Pozza
G. Puliani
P. Razzore
S. Ramponi
S. Ricciardi
L. Rizza
F. Rota
E. Sbardella
M. C. Zatelli
机构
[1] University of Turin,Oncological Endocrinology Unit, Department of Medical Sciences
[2] ASL Verbano Cusio Ossola,Endocrinology and Diabetology Unit
[3] AO San Camillo-Forlanini,Oncology Unit, Department of Oncology and Medical Specialities
[4] Fondazione IRCCS Istituto Nazionale Tumori Milano,ENETS Center of Excellence, Department of Medical Oncology
[5] Sapienza University of Rome,Department of Experimental Medicine, AO S. Andrea
[6] Federico II University Medical School of Naples,Endocrinology Unit, Department of Clinical Medicine and Surgery
[7] AO San Camillo-Forlanini,Endocrinology Unit, Department of Oncology and Medical Specialities
[8] University of Messina,Endocrine Unit, Department of Clinical and Experimental Medicine
[9] AOU Policlinico G. Martino,Department of Experimental Medicine
[10] Sapienza University of Rome,undefined
来源
Reviews in Endocrine and Metabolic Disorders | 2021年 / 22卷
关键词
Cancer; Obesity; Overweight; Body mass index; Cancer therapy; Treatment outcome;
D O I
暂无
中图分类号
学科分类号
摘要
Obesity, whose prevalence is pandemic and continuing to increase, is a major preventable and modifiable risk factor for diabetes and cardiovascular diseases, as well as for cancer. Furthermore, epidemiological studies have shown that obesity is a negative independent prognostic factor for several oncological outcomes, including overall and cancer-specific survival, for several site-specific cancers as well as for all cancers combined. Yet, a recently growing body of evidence suggests that sometimes overweight and obesity may associate with better outcomes, and that immunotherapy may show improved response among obese patients compared with patients with a normal weight. The so-called ‘obesity paradox’ has been reported in several advanced cancer as well as in other diseases, albeit the mechanisms behind this unexpected relationship are still not clear. Aim of this review is to explore the expected as well as the paradoxical relationship between obesity and cancer prognosis, with a particular emphasis on the effects of cancer therapies in obese people.
引用
收藏
页码:681 / 702
页数:21
相关论文
共 1277 条
  • [11] Polite BN(2014)Obesity is associated with a poorer prognosis in women with hormone receptor positive breast cancer Maturitas 79 279-286
  • [12] Yothers G(2014)Effect of obesity on aromatase inhibitor efficacy in postmenopausal, hormone receptor-positive breast cancer: a systematic review Breast Cancer Res Treat 147 237-248
  • [13] Raich P(2016)Obesity and breast Cancer prognosis: evidence, challenges, and opportunities J Clin Oncol 34 4203-4216
  • [14] Colangelo L(2017)Interaction between body mass index and hormone-receptor status as a prognostic factor in lymph-node-positive breast cancer PLoS One 12 7363-7374
  • [15] O'Connell MJ(2018)Body mass index and prognosis of breast cancer: an analysis by menstruation status when breast cancer diagnosis Medicine (Baltimore) 97 8-127
  • [16] Wolmark N(2019)Body mass index and diabetes are important prognostic signatures for bilateral breast cancer prognosis J Cell Biochem 120 121-746
  • [17] Meyerhardt JA(2016)Impact of body weight and body composition on ovarian Cancer prognosis Curr Oncol Rep 18 741-634
  • [18] Niedzwiecki D(2009)Endometrial cancer and obesity: epidemiology, biomarkers, prevention and survivorship Gynecol Oncol 114 625-3886
  • [19] Hollis D(2006)Greater body mass index is associated with better pathologic features and improved outcome among patients treated surgically for clear cell renal cell carcinoma Urology 68 dju177-112
  • [20] Saltz LB(2013)Body mass index and survival in patients with renal cell carcinoma: a clinical-based cohort and meta-analysis Int J Cancer 132 3869-514